TSC1-mTOR signaling and T cell tolerance
TSC1-mTOR 信号传导和 T 细胞耐受
基本信息
- 批准号:8462905
- 负责人:
- 金额:$ 36.9万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2012
- 资助国家:美国
- 起止时间:2012-05-01 至 2017-04-30
- 项目状态:已结题
- 来源:
- 关键词:1,2-diacylglycerolAutoimmune DiseasesAutophagocytosisCD4 Positive T LymphocytesCell LineCell SurvivalCell physiologyCessation of lifeComplexDataDevelopmentDiacylglycerol KinaseDiglyceridesDiseaseEnzymesGenerationsGenetic TranscriptionGoalsGraft RejectionHelper-Inducer T-LymphocyteHomeostasisImmune ToleranceImmune responseImmunosuppressive AgentsImpairmentMalignant NeoplasmsMemoryMitochondriaModelingMouse Cell LineMusNutrientPathogenesisPathway interactionsPeripheralPlayPropertyProtein-Serine-Threonine KinasesRegulatory T-LymphocyteResistanceRoleSignal TransductionSirolimusT cell anergyT cell differentiationT cell responseT-Cell ActivationT-Cell ReceptorT-LymphocyteTestingThymus GlandTranslationsTransplantationTumor Suppressor ProteinsViralanergyimmune functionimprovedinsightmTOR proteinnovelnovel therapeuticspathogenpreventpublic health relevancetumorubiquitin-protein ligaseuptake
项目摘要
DESCRIPTION (provided by applicant): T cell tolerance not only is critical in preventing autoimmune diseases but also contributes to tumor tolerance. T cell anergy and regulatory T cells (Treg) are two major forms of peripheral T cell tolerance. However, the specific mechanisms that control T cell anergy and Treg are still not well understood. Rapamycin has been utilized as an immunosuppressant for decades. Its target, the mammalian target of rapamycin (mTOR), is a serine threonine kinase that plays crucial roles in multiple cellular processes by regulating nutrient uptake, transcription, translation, autophagy, and cell survival. mTOR forms two signaling complexes (mTORC1 and mTORC2) with distinct signaling properties and sensitivities to rapamycin. Recent evidence has established mTOR as a crucial regulator for effector T cell differentiation, T cell anergy, inducible regulatory T cell differentiation, and memory T cell responses to viral pathogens. However, the pathways leading to mTOR activation in T cells and the importance of tight control of mTOR activity remain poorly understood. The objective of this proposal is to improve the understanding of mTOR signaling and the importance of the tumor suppressor tuberous complex 1 (TSC1) as a critical regulator for mTOR in the control of T cell tolerance. Using genetically manipulated mice and cell line models, we have recently revealed that the RasGRP1-Ras- Mek1/2-Erk1/2 pathway is critical for both mTORC1 and mTORC2 activation in T cells following T cell receptor (TCR) stimulation. We and others have also demonstrated that TSC1 inhibits mTORC1 but promotes mTORC2 signaling in T cells and is important for normal T cell homeostasis. Our central hypotheses for this proposal are 1) multiple signaling cascades downstream of the TCR control mTOR activation and 2) TSC1 is a critical regulator for inducible Treg and T cell anergy by tight contro of mTORC1 and mTORC2 signaling. With strong preliminary data, we plan to test our hypotheses by pursuing three specific aims. In aim 1, we will investigate the mechanisms that control mTOR activation in T cells. We will test the hypothesis that Erk1/2 phosphorylate multiple substrates to promote mTORC1 and mTORC2 activation. In aim 2, we will determine how TSC1 controls T cell anergy. In aim 3, we will determine how TSC1 controls inducible Treg and helper T cell differentiation. The proposed studies will provide new insight into the understanding of mTOR signaling, the importance of TSC1 in T cells, and the mechanisms modulating T cell tolerance.
描述(由申请人提供):T细胞耐受性不仅在预防自身免疫性疾病中至关重要,而且有助于肿瘤耐受性。T细胞无能和调节性T细胞(Treg)是外周T细胞耐受的两种主要形式。然而,控制T细胞无反应性和Treg的具体机制仍不清楚。几十年来,雷帕霉素一直被用作免疫抑制剂。它的靶点,雷帕霉素的哺乳动物靶点(mTOR),是一种丝氨酸苏氨酸激酶,通过调节营养摄取、转录、翻译、自噬和细胞存活在多种细胞过程中发挥关键作用。mTOR形成两种信号传导复合物(mTORC 1和mTORC 2),其具有不同的信号传导特性和对雷帕霉素的敏感性。最近的证据已经确定mTOR是效应T细胞分化、T细胞无反应性、诱导型调节性T细胞分化和记忆T细胞对病毒病原体应答的关键调节因子。然而,导致T细胞中mTOR活化的途径以及严格控制mTOR活性的重要性仍然知之甚少。该提案的目的是提高对mTOR信号传导的理解,以及肿瘤抑制结节复合物1(TSC 1)作为mTOR在T细胞耐受性控制中的关键调节剂的重要性。使用遗传操作的小鼠和细胞系模型,我们最近揭示了RasGRP 1-Ras-Mek 1/2-Erk 1/2通路对于T细胞受体(TCR)刺激后T细胞中的mTORC 1和mTORC 2活化都是至关重要的。我们和其他人还证明了TSC 1抑制mTORC 1,但促进T细胞中的mTORC 2信号传导,并且对正常T细胞稳态很重要。我们对这一提议的中心假设是1)TCR下游的多个信号级联控制mTOR活化和2)TSC 1是通过mTORC 1和mTORC 2信号传导的紧密控制的诱导性Treg和T细胞无反应性的关键调节剂。有了强有力的初步数据,我们计划通过追求三个具体目标来测试我们的假设。在目标1中,我们将研究控制T细胞中mTOR激活的机制。我们将检验Erk 1/2磷酸化多种底物以促进mTORC 1和mTORC 2活化的假设。在目标2中,我们将确定TSC 1如何控制T细胞无能。在目标3中,我们将确定TSC 1如何控制诱导型Treg和辅助性T细胞分化。拟议的研究将为理解mTOR信号传导,TSC 1在T细胞中的重要性以及调节T细胞耐受性的机制提供新的见解。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
XIAOPING ZHONG其他文献
XIAOPING ZHONG的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('XIAOPING ZHONG', 18)}}的其他基金
Strawberry notch homologues in T cell homeostasis and function
T 细胞稳态和功能中的草莓缺口同源物
- 批准号:
10543152 - 财政年份:2021
- 资助金额:
$ 36.9万 - 项目类别:
Strawberry notch homologues in T cell homeostasis and function
T 细胞稳态和功能中的草莓缺口同源物
- 批准号:
10219905 - 财政年份:2021
- 资助金额:
$ 36.9万 - 项目类别:
Strawberry notch homologues in T cell homeostasis and function
T 细胞稳态和功能中的草莓缺口同源物
- 批准号:
10331339 - 财政年份:2021
- 资助金额:
$ 36.9万 - 项目类别:
TSC1-mTOR signaling and T cell tolerance
TSC1-mTOR 信号传导和 T 细胞耐受
- 批准号:
8831584 - 财政年份:2012
- 资助金额:
$ 36.9万 - 项目类别:
TSC1-mTOR signaling and T cell tolerance
TSC1-mTOR 信号传导和 T 细胞耐受
- 批准号:
8346442 - 财政年份:2012
- 资助金额:
$ 36.9万 - 项目类别:
TSC1-mTOR signaling and T cell tolerance
TSC1-mTOR 信号传导和 T 细胞耐受
- 批准号:
9062374 - 财政年份:2012
- 资助金额:
$ 36.9万 - 项目类别:
TSC1-mTOR signaling and T cell tolerance
TSC1-mTOR 信号传导和 T 细胞耐受
- 批准号:
8652947 - 财政年份:2012
- 资助金额:
$ 36.9万 - 项目类别:
相似国自然基金
Autoimmune diseases therapies: variations on the microbiome in rheumatoid arthritis
- 批准号:31171277
- 批准年份:2011
- 资助金额:60.0 万元
- 项目类别:面上项目
相似海外基金
Autoantibodies and antibody-secreting cells in neurological autoimmune diseases: from biology to therapy
神经性自身免疫性疾病中的自身抗体和抗体分泌细胞:从生物学到治疗
- 批准号:
479128 - 财政年份:2023
- 资助金额:
$ 36.9万 - 项目类别:
Operating Grants
Effects of maternal immune activation on autoimmune diseases in offsprings
母体免疫激活对后代自身免疫性疾病的影响
- 批准号:
23H02155 - 财政年份:2023
- 资助金额:
$ 36.9万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
IPP: AUTOIMMUNE DISEASES STATISTICAL AND CLINICAL COORDINATING CENTER (ADSCCC)
IPP:自身免疫性疾病统计和临床协调中心 (ADSCCC)
- 批准号:
10788032 - 财政年份:2023
- 资助金额:
$ 36.9万 - 项目类别:
Biomarkers of vascular endothelial dysfunction in systemic autoimmune diseases: analysis of circulating microRNAs
系统性自身免疫性疾病中血管内皮功能障碍的生物标志物:循环 microRNA 分析
- 批准号:
23K14742 - 财政年份:2023
- 资助金额:
$ 36.9万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
NOVEL HUMORAL AND CELLULAR BIOMARKERS OF AUTOIMMUNE DISEASES CAUSED BY IMMUNOTHERAPY
免疫治疗引起的自身免疫性疾病的新型体液和细胞生物标志物
- 批准号:
10593224 - 财政年份:2023
- 资助金额:
$ 36.9万 - 项目类别:
Structural mechanisms of autoimmune diseases targeting cys-loop receptors
针对半胱氨酸环受体的自身免疫性疾病的结构机制
- 批准号:
10864719 - 财政年份:2023
- 资助金额:
$ 36.9万 - 项目类别:
Developing non-immunosuppressive immune-based therapeutics for targeted treatment of autoimmune diseases
开发非免疫抑制性免疫疗法来靶向治疗自身免疫性疾病
- 批准号:
10586562 - 财政年份:2023
- 资助金额:
$ 36.9万 - 项目类别:
Regulation of autoimmune diseases by PTPN22 phosphatase
PTPN22磷酸酶对自身免疫性疾病的调节
- 批准号:
23K06589 - 财政年份:2023
- 资助金额:
$ 36.9万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Decipher and target GABA metabolism and GABA receptor-mediated signaling in autoimmune diseases
破译并靶向自身免疫性疾病中的 GABA 代谢和 GABA 受体介导的信号传导
- 批准号:
10623380 - 财政年份:2023
- 资助金额:
$ 36.9万 - 项目类别:
Targeting the long isoform of the prolactin receptor to treat autoimmune diseases and B-cell malignancies
靶向催乳素受体的长亚型来治疗自身免疫性疾病和 B 细胞恶性肿瘤
- 批准号:
10735148 - 财政年份:2023
- 资助金额:
$ 36.9万 - 项目类别: